A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy

Journal of the National Cancer Institute

Volumn 104, Issue 9, 2012, Pages 670-681

  Kang, Josephine ^a   D'Andrea, Alan D ^b   Kozono, David ^b  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CISPLATIN; OXALIPLATIN;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; CYSTADENOCARCINOMA; DNA DAMAGE; DNA REPAIR; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; DISEASE-FREE SURVIVAL; DNA REPAIR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862188915     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs177     Document Type: Article

References (56)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Pignata S, Cannella L, Leopardo D, et al. Chemotherapy in epithelial ovarian cancer. Cancer Lett. 2011;303(2):73-83.
3. Barakat RR, Markman M, Randall ME. Principles and Practice of Gynecologic Oncology. 5 ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009.
4. Kunos CA, Sill MW, Buekers TE, et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol. 2011;120(2):224-228.
5. Herzog TJ. Clinical experience with topotecan in relapsed ovarian cancer. Gynecol Oncol. 2003;90(3, pt 2):S3-S7.
6. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16):4722-4729.
7. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11(18):6422-6430.
8. Shridhar V, Lee J, Pandita A, et al. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001;61(15):5895-5904.
9. Berchuck A, Iversen ES, Lancaster JM, et al. Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res. 2005;11(10):3686-3696.
10. Spentzos D, Levine DA, Ramoni MF, et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol. 2004;22(23):4700-4710.
11. Tothill RW, Tinker AV, George J, et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008;14(16):5198-5208.
12. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res. 2005;11(17):6300-6310.
13. Hartmann LC, Lu KH, Linette GP, et al. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005;11(6):2149-2155.
14. Konstantinopoulos PA, Spentzos D, Karlan BY, et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol. 2010;28(22):3555-3561.
15. Park JS, Young Yoon S, Kim JM, et al. Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett. 2004;214(1):19-33.
16. Tanaka AR, Tanabe K, Morita M, et al. ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1). J Biol Chem. 2002;277(42):40142-40147.
17. Do JH, Choi DK. Clustering approaches to identifying gene expression patterns from DNA microarray data. Mol Cells. 2008;25(2):279-288.
18. Yazlovitskaya EM, Persons DL. Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin. Anticancer Res. 2003;23(3B):2275-2279.
19. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. 2007;6(9):1006-1010.
20. Kennedy RD, Chen CC, Stuckert P, et al. Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest. 2007;117(5):1440-1449.
21. D'Andrea AD. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers. Cell Cycle. 2003;2(4):290-292.
22. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell defects in homologous recombination. Anticancer Agents Med Chem. 2008;8(4):448-460.
23. Basu A, Krishnamurthy S. Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010;2010. pii: 201367.
24. Hicks JK, Chute CL, Paulsen MT, et al. Differential roles for DNA polymerases eta, zeta, and REV1 in lesion bypass of intrastrand versus interstrand DNA cross-links. Mol Cell Biol. 2010;30(5):1217-1230.
25. Kim YJ, Wilson DM III. Overview of base excision repair biochemistry [published online ahead of print]. Curr Mol Pharmacol. 2011.
26. Zharkov DO. Base excision DNA repair. Cell Mol Life Sci. 2008;65(10):1544-1565.
27. Duncan T, Trewick SC, Koivisto P, et al. Reversal of DNA alkylation damage by two human dioxygenases. Proc Natl Acad Sci U S A. 2002;99(26):16660- 16665.
28. Hazra TK, Izumi T, Kow YW, et al. The discovery of a new family of mammalian enzymes for repair of oxidatively damaged DNA, and its physiological implications. Carcinogenesis. 2003;24(2):155-157.
29. Lin Y, Wilson JH. Diverse effects of individual mismatch repair components on transcription-induced CAG repeat instability in human cells. DNA Repair (Amst). 2009;8(8):878-885.
30. Martinez SL, Kolodner RD. Functional analysis of human mismatch repair gene mutations identifies weak alleles and polymorphisms capable of polygenic interactions. Proc Natl Acad Sci U S A. 2010;107(11):5070-5075.
31. Acharya S, Wilson T, Gradia S, et al. hMSH2 forms specific mispair-binding complexes with hMSH3 and hMSH6. Proc Natl Acad Sci U S A. 1996;93(24):13629-13634.
32. Barker CA, Powell SN. Enhancing radiotherapy through a greater understanding of homologous recombination. Semin Radiat Oncol. 2010;20(4):267-273.e3.
33. Gomes BC, Silva SN, Azevedo AP, et al. The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol Rep. 2010;24(4):1079-1085.
34. Takedachi A, Saijo M, Tanaka K. DDB2 complex-mediated ubiquitylation around DNA damage is oppositely regulated by XPC and Ku and contributes to the recruitment of XPA. Mol Cell Biol. 2010;30(11):2708-2723.
35. Hemphill AW, Bruun D, Thrun L, et al. Mammalian SNM1 is required for genome stability. Mol Genet Metab. 2008;94(1):38-45.
36. Hlavin EM, Smeaton MB, Miller PS. Initiation of DNA interstrand cross-link repair in mammalian cells. Environ Mol Mutagen. 2010;51(6):604-624.
37. Marini F, Kim N, Schuffert A, et al. POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308. J Biol Chem. 2003;278(34):32014-32019.
38. Khakhar RR, Cobb JA, Bjergbaek L, et al. RecQ helicases: multiple roles in genome maintenance. Trends Cell Biol. 2003;13(9):493-501.
39. Hickson ID. RecQ helicases: caretakers of the genome. Nat Rev Cancer. 2003;3(3):169-178.
40. Bradsher J, Coin F, Egly JM. Distinct roles for the helicases of TFIIH in transcript initiation and promoter escape. J Biol Chem. 2000;275(4):2532-2538.
41. Marini F, Wood RD. A human DNA helicase homologous to the DNA cross-link sensitivity protein Mus308. J Biol Chem. 2002;277(10):8716-8723.
42. Broderick S, Rehmet K, Concannon C, et al. Eukaryotic single-stranded DNA binding proteins: central factors in genome stability. Subcell Biochem. 2010;50:143-163.
43. Balajee AS, May A, Dianova I, et al. Efficient PCNA complex formation is dependent upon both transcription coupled repair and genome overall repair. Mutat Res. 1998;409(3):135-146.
44. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609-615.
45. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228-247.
46. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000;70(2):209-262.
47. International Federation of Gynecology and Obstetrics. Classification and staging of malignant tumours in the female pelvis. Acta Obstet Gynecol Scand. 1971;50(1):1-7.
48. Gallagher DJ, Konner JA, Bell-McGuinn KM, et al. Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. Ann Oncol. 2011;22(5):1127-1132.
49. Tutt AN, Lord CJ, McCabe N, et al. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb Symp Quant Biol. 2005;70:139-148.
50. Cass I, Baldwin RL, Varkey T, et al. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97(9):2187-2195.
51. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 2006;66(16):8109-8115.
52. Tan DS, Rothermundt C, Thomas K, et al. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008;26(34):5530-5536.
53. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28(15):2512-2519.
54. Landau DA, Slack FJ. MicroRNAs in mutagenesis, genomic instability, and DNA repair. Semin Oncol. 2011;38(6):743-751.
55. Keith CT, Schreiber SL. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science. 1995;270(5233):50-51.
56. Dianov GL, Meisenberg C, Parsons JL. Regulation of DNA repair by ubiquitylation. Biochemistry (Mosc). 2011;76(1):69-79.